COVID-19 - March 28, 2022
AstraZeneca’s Evusheld approved in the EU
AstraZeneca’s Evusheld, a long-acting antibody combination, has been granted marketing authorization in the European Union (EU) for the pre-exposure prophylaxis (prevention) of COVID-19 in a broad population of adults and adolescents aged 12 years and older weighing at least 40 kg. The approval by the European Commission was based on results from the Evusheld clinical […]
Clinical Trials - March 28, 2022
AstraZeneca’s CALLA trial did not achieve statistical significance for the primary endpoint
The CALLA Phase III trial for AstraZeneca’s Imfinzi given concurrently with chemoradiotherapy (CRT) did not achieve statistical significance for the primary endpoint of improving progression-free survival (PFS) versus CRT alone in the treatment of patients with locally advanced cervical cancer. “CALLA tested a novel immunotherapy approach in locally advanced cervical cancer, a devastating and complex […]
COVID-19 - March 25, 2022
AstraZeneca’s Evusheld recommended for approval in the EU
AstraZeneca’s Evusheld, a long-acting antibody combination, has been recommended for marketing authorization in the EU for the pre-exposure prophylaxis (prevention) of COVID-19 in a broad population of adults and adolescents aged 12 years and older weighing at least 40 kg. People not adequately protected by a COVID-19 vaccine may particularly benefit from pre-exposure prophylaxis with […]
Intellectual Property - March 17, 2022
AstraZeneca reaches settlement agreement
Alexion, AstraZeneca’s Rare Disease group, has entered into a settlement agreement with Chugai Pharmaceutical, resolving all patent disputes between the two companies related to Ultomiris (ravulizumab). In accordance with the settlement agreement, Alexion and Chugai have taken steps to withdraw patent infringement proceedings filed with US District Court for the District of Delaware and Tokyo […]
Collaboration - March 16, 2022
AstraZeneca and Business Tampere offer a mentoring program
AstraZeneca offers ”one-off” business mentoring sessions for selected startups that are aspiring business and collaboration with the pharma industry. The application period for the mentoring program is open now and applicants all around Finland are welcome, reports Business Tampere. A unique opportunity “This is a unique opportunity and Tampere is the only location in Finland […]
Pharma Business - March 15, 2022
AstraZeneca’s Lynparza approved in the US
AstraZeneca and MSD’s Lynparza has been approved in the US for the adjuvant treatment of patients with germline BRCA-mutated HER2-negative high-risk early breast cancer who have already been treated with chemotherapy either before or after surgery. The approval by the US Food and Drug Administration (FDA) was based on results from the OlympiA Phase III […]
